Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Glaukos Corp (GKOS)
Glaukos Corp stock price live, this page displays NYSE GKOS stock exchange data. View the GKOS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Glaukos Corp real time stock price chart below.
What Is the Glaukos Corp Stock Price Today?
The Glaukos Corp stock price today is 86.55.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is ""GKOS.""
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the NYSE stock exchange.
Is Glaukos Corp a Good Stock to Buy?
Determining whether Glaukos Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GKOS quote. (ISIN: US3773221029)
What Is the Glaukos Corp Stock Price Today?
The Glaukos Corp stock price today is 86.55.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is ""GKOS.""
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the NYSE stock exchange.
Is Glaukos Corp a Good Stock to Buy?
Determining whether Glaukos Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GKOS quote. (ISIN: US3773221029)
NYSE
Currency in USD
86.55
-0.95(-1.09%)
Real-time Data·
Fair Value
An estimate of a Glaukos Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
84.58
87.09
52 wk Range
77.10
163.71
GKOS Scorecard
Full Analysis
6 analysts have revised their earnings downwards for the upcoming period
GKOS is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Glaukos Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
84.5887.09
52 wk Range
77.10163.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GKOS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Glaukos Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
123.08
Upside
+42.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Glaukos Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Glaukos Corp Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corp Earnings Call Summary for Q2/2025
- Glaukos Corp beats Q2 2025 estimates: EPS of -$0.24 vs -$0.26 forecast, revenue of $124.1M vs $115.52M expected
- Revenue grew 30% YoY, with U.S. Glaucoma sales up 45%; stock dipped 0.28% in aftermarket trading to $93.5
- Full-year 2025 sales guidance raised to $480-$486M; company expects regulatory approval for Epioxa in October 2025
- CEO highlights pioneering efforts in new therapeutic categories, noting increased clinical interest in innovative treatments
- Challenges include navigating MAC reimbursement, potential supply chain disruptions, and regulatory hurdles for new products
Last Updated: 30/07/2025, 23:54
Read Full TranscriptCompare GKOS to Peers and Sector
Metrics to compare | GKOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGKOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −53.2x | −3.6x | −0.5x | |
PEG Ratio | −1.11 | −0.19 | 0.00 | |
Price/Book | 6.5x | 2.4x | 2.6x | |
Price / LTM Sales | 11.4x | 2.4x | 3.3x | |
Upside (Analyst Target) | 39.4% | 20.0% | 43.5% | |
Fair Value Upside | Unlock | 4.0% | 6.3% | Unlock |
Analyst Ratings
11 Buy
2 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 123.08
(+42.21% Upside)
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
-0.24 / -0.26
Revenue / Forecast
124.01M / 115.52M
People Also Watch
FAQ
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is "GKOS."
What Is the Glaukos Corp Market Cap?
As of today, Glaukos Corp market cap is 4.97B.
What Is Glaukos Corp's Earnings Per Share (TTM)?
The Glaukos Corp EPS (TTM) is -1.65.
When Is the Next Glaukos Corp Earnings Date?
Glaukos Corp will release its next earnings report on 28 Oct 2025.
From a Technical Analysis Perspective, Is GKOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Glaukos Corp Stock Split?
Glaukos Corp has split 0 times.
How Many Employees Does Glaukos Corp Have?
Glaukos Corp has 995 employees.
What is the current trading status of Glaukos Corp (GKOS)?
As of 05 Aug 2025, Glaukos Corp (GKOS) is trading at a price of 86.55, with a previous close of 87.50. The stock has fluctuated within a day range of 84.58 to 87.09, while its 52-week range spans from 77.10 to 163.71.
What Is Glaukos Corp (GKOS) Price Target According to Analysts?
The average 12-month price target for Glaukos Corp is USD123.08333, with a high estimate of USD165 and a low estimate of USD72. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +42.21% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.